Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07303777) titled 'Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis' on Dec. 23, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Atom Therapeutics Co., Ltd
Condition:
Atherosclerosis Cardiovascular Disease
ASCVD
ASCVD Management
Intervention:
Drug: ABP-745 Dose A
Drug: Placebo
Drug: ABP-745 Dose B
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: February 2026
Target Sample Size:...